SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB

類似資料

• Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
  著者:: Avery, Robert L, 等
  出版事項: (2014)
• Residual edema evaluation with ranibizumab 0.5 mg and 2.0 mg formulations for diabetic macular edema (REEF study)
  著者:: Dhoot, D S, 等
  出版事項: (2015)
• Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy
  著者:: Jung, Byung Ju, 等
  出版事項: (2019)
• The Comparative Risk of Endophthalmitis Following Intravitreal Injection with Bevacizumab, Aflibercept, and Ranibizumab
  著者:: Bavinger, J. Clay, 等
  出版事項: (2019)
• Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
  著者:: Fouda, Sameh Mosaad, 等
  出版事項: (2017)